Timothy Minh-Tien Dang, MD
Dermatology · San Diego
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Offices
- 5
Offices
5 locations · Regents of the University of California · 2,047 clinicians in this group
Hospitals listed: UC San Diego Health Hillcrest - Hillcrest Med Ctr. That is not proof they admit you there this week.
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dr. Dang’s office to ask if they take your plan before you enroll.
California Medical Board record
Licence A186246 · Current
Licensed to practise in California · since 2023 · expires 2027-05-31 · Stanford University School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- UC San Diego Health Hillcrest - Hillcrest Med CtrSan Diego, CAAcute Care Hospital · Voluntary non-profit - Other · Has an emergency department · Birthing-friendlyPart of University of California Health, which runs 12 hospitalsHome of Moores Comprehensive Cancer Center, a National Cancer Institute designated comprehensive cancer centrePatients rate it 3 of 5 · 75% would definitely recommend itOverall rating: 5 of 5 starsBetter than the national rate — Death rate among surgical inpatients with serious treatable complications: 105.39 (74.34 to 136.44) · 381 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.597, Oct 2024 – Sep 2025Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.618, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.375, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.376, Oct 2024 – Sep 2025
See every measure and the patient survey for UC San Diego Health Hillcrest - Hillcrest Med Ctr
Behind the star rating — Deaths: 6 better, 2 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 1 better, 8 the same, 2 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 105.39 (74.34 to 136.44) · 381 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.597 | Better | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.618 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.375 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.376 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.83 (0.11 to 1.54) · 3,862 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.02 (0.84 to 1.2) | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.4 · 130 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.2 · 116 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.1 · 183 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 7.8 · 510 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 11 · 696 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 9.4 · 435 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 5,739 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.15 (0 to 0.32) · 12,387 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.27 (0.1 to 0.44) · 13,596 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 4.59 (3.24 to 5.94) · 4,389 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.04 (0 to 2.12) · 2,419 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.26 (1.23 to 3.29) · 4,116 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 9.93 (6.61 to 13.25) · 2,232 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 7.31 (5.24 to 9.38) · 2,410 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 2.32 (1.07 to 3.56) · 1,286 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.38 (0.02 to 0.75) · 11,838 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.5 · 181 cases | None | Apr 2023 – Mar 2025 |
| MRSA BacteremiaInfections | 0.716 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.672 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.5 · 302 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 19.3 · 891 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 3.8 · 216 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 5.9 · 620 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 12 · 731 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 15.7 · 946 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.9 (4.8 to 7) · 1,507 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 12.3 (10.7 to 14) · 1,507 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 7.1 · 191 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.7 · 177 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.7 · 204 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 10.4 (8.5 to 13) · 4,116 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.9 (0.7 to 1) · 2,130 cases | No different | Jan 2024 – Dec 2024 |
What patients said (3,680 patients answered, 16% of those asked)
| Cleanliness | 3 |
| Nurse communication | 3 |
| Doctor communication | 3 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 4 |
| Room was "always" clean | 66% |
| Nurses "always" communicated well | 79% |
| Doctors "always" communicated well | 79% |
| Staff "always" explained | 61% |
| Yes, staff "did" give patients this information | 88% |
| Yes, staff "did" give patients information about help after discharge | 87% |
| Doctors "always" explained things so they could understand | 75% |
| Doctors "always" listened carefully | 78% |
| Doctors "always" treated them with courtesy and respect | 86% |
| Patients who gave a rating of "9" or "10" (high) | 73% |
| Staff "always" explained new medications | 73% |
| Nurses "always" explained things so they could understand | 75% |
| Nurses "always" listened carefully | 75% |
| Nurses "always" treated them with courtesy and respect | 86% |
| "Always" quiet at night | 49% |
| "YES", patients would definitely recommend the hospital | 75% |
| Staff "always" explained possible side effects | 48% |
| Yes, staff "did" give patients information about possible symptoms | 88% |
Original Medicare doctor bills
$130,915
Medicare paid this office $130,915 for 560 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Return visit (30+ min) | 209 | $28,890 | $100 |
| Destruction of skin growth, 1-14 growths | 108 | $11,715 | $93 |
| Return visit (30+ min) | 74 | $9,074 | $74 |
| Short return visit (20+ min) | 106 | $8,767 | $71 |
| New patient visit (45+ min) | 70 | $8,538 | $122 |
See all 26 services
| Return visit (30+ min) | 209 | $28,890 | $100 |
| Destruction of skin growth, 1-14 growths | 108 | $11,715 | $93 |
| Return visit (30+ min) | 74 | $9,074 | $74 |
| Short return visit (20+ min) | 106 | $8,767 | $71 |
| New patient visit (45+ min) | 70 | $8,538 | $122 |
| Long return visit (40+ min) | 38 | $8,122 | $116 |
| Destruction of precancer skin growth, 1 growth | 130 | $5,773 | $40 |
| Destruction of precancer skin growth, 15 or more growths | 36 | $5,770 | $137 |
| Biopsy of related skin growth, first growth | 66 | $4,766 | $67 |
| New patient visit (45+ min) | 47 | $4,720 | $100 |
| New patient visit (30+ min) | 46 | $3,819 | $83 |
| Long return visit (40+ min) | 21 | $3,512 | $140 |
| Destruction of precancer skin growth, 2-14 growths | 101 | $3,055 | $6 |
| New patient visit (60+ min) | 18 | $2,657 | $148 |
| Destruction of skin growth, 1-14 growths | 27 | $1,986 | $55 |
| Punch biopsy, first skin growth | 16 | $1,746 | $103 |
| Destruction of precancer skin growth, 1 growth | 37 | $1,433 | $35 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 57 | $1,350 | $14 |
| Short return visit (20+ min) | 19 | $1,181 | $51 |
| New patient visit (30+ min) | 19 | $1,071 | $56 |
| Application of ultraviolet light to skin | 11 | $880 | $23 |
| Punch biopsy, first skin growth | 22 | $817 | $37 |
| Biopsy of related skin growth, first growth | 23 | $632 | $26 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 23 | $392 | $14 |
| Destruction of precancer skin growth, 2-14 growths | 29 | $179 | $2 |
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 12 | $15 | None |
Procedures Medicare counted
| Removal of skin lesions | 535 | More than 87% of doctors who do this |
| Removal or shaving of skin growth | 33 | More than 76% of doctors who do this |
| Skin biopsy | 178 | More than 83% of doctors who do this |
Who their Medicare patients are
560 Original Medicare patients in 2024. Average age 74 · Under 65 9% · 85 and older 10% · Women 47% · Also on Medicaid 19% · Health risk score 1.66. Sicker patients than 9 in 10 peers; the typical dermatology clinician is at 1.01.
Conditions among them: High blood pressure 64% · Cancer 28% · Coronary heart disease 25% · Depression 24% · Chronic kidney disease 22% · Diabetes 19% · Atrial fibrillation 18% · COPD 15% · Heart failure 14% · Stroke 6% · Dementia 5%.
The office billed $660,979, Medicare allowed $177,260 and paid $130,915; for 2,337 services of 40 kinds; $15 of it was for drugs given in the office and $130,900 for care.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 560 | 2,337 | 74 | 1.66 | $660,979 | $130,915 |
| 2023 | 291 | 886 | 73 | 1.41 | $223,937 | $53,675 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 11 services
| Return visit (30+ min) | 92 | $11,045 | $106 |
| New patient visit (45+ min) | 62 | $8,592 | $139 |
| Destruction of skin growth, 1-14 growths | 50 | $5,293 | $102 |
| Short return visit (20+ min) | 58 | $4,555 | $77 |
| New patient visit (30+ min) | 48 | $4,055 | $84 |
| Biopsy of related skin growth, first growth | 43 | $3,622 | $80 |
| Destruction of precancer skin growth, 1 growth | 68 | $3,156 | $45 |
| Destruction of precancer skin growth, 2-14 growths | 53 | $1,610 | $6 |
| Return visit (30+ min) | 19 | $1,610 | $80 |
| Punch biopsy, first skin growth | 13 | $1,474 | $113 |
| Biopsy of related skin growth, each additional growth | 14 | $919 | $44 |
Medicaid work
$377 in 2023
Medicaid paid $377 for 12 billed services this clinician did in 2023, up to 12 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Return visit (30+ min) | 12 | $377 |
| 2023 | 12 | 1 | 12 | $377 |
Drugs they prescribed that Part D paid
$1,223,938
Pharmacies billed $1,223,938 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 1,483) in 2024. At or below the middle of the specialty; the typical dermatology clinician is at 0%.
1,258 generic and 225 brand-name prescriptions · $1,223,938 in drug cost · 65 antibiotic prescriptions to 30 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Dupixent | 93 | $345,678 | $3,717 |
| Skyrizi | 17 | $319,577 | $18,799 |
| Humira(Cf) | 12 | $144,026 | $12,002 |
| Otezla | 29 | $112,776 | $3,889 |
| Opzelura | 11 | $26,208 | $2,383 |
See all 30 drugs
| Dupixent | 93 | $345,678 | $3,717 |
| Skyrizi | 17 | $319,577 | $18,799 |
| Humira(Cf) | 12 | $144,026 | $12,002 |
| Otezla | 29 | $112,776 | $3,889 |
| Opzelura | 11 | $26,208 | $2,383 |
| Zoryve | 13 | $10,844 | $834 |
| Acitretin | 17 | $10,092 | $594 |
| Clobetasol Propionate | 119 | $5,518 | $46 |
| Tacrolimus | 38 | $5,117 | $135 |
| Tazarotene | 14 | $4,600 | $329 |
| Fluorouracil | 56 | $3,426 | $61 |
| Fluocinonide | 80 | $2,514 | $31 |
| Ketoconazole | 169 | $2,383 | $14 |
| Triamcinolone Acetonide | 159 | $1,954 | $12 |
| Metronidazole | 23 | $1,283 | $56 |
| Betamethasone Diprop Augmented | 28 | $1,101 | $39 |
| Doxycycline Hyclate | 46 | $886 | $19 |
| Clindamycin Phosphate | 32 | $865 | $27 |
| Ciclopirox | 25 | $826 | $33 |
| Dexamethasone | 22 | $576 | $26 |
| Pilocarpine | 12 | $564 | $47 |
| Mupirocin | 97 | $545 | $6 |
| Clotrimazole | 19 | $397 | $21 |
| Imiquimod | 18 | $329 | $18 |
| Econazole Nitrate | 15 | $296 | $20 |
| Hydrocortisone | 71 | $252 | $4 |
| Minoxidil | 19 | $220 | $12 |
| Valacyclovir | 11 | $198 | $18 |
| Fluconazole | 17 | $155 | $9 |
| Prednisone | 16 | $110 | $7 |
Year by year
| 2024 | 1,483 | 401 | 0% (0) | 15% | $1,223,938 |
| 2023 | 506 | 226 | 0% (0) | 9% | $211,603 |
| 2022 | 209 | 99 | 0% (0) | 10% | $18,509 |
| 2021 | 161 | 83 | 0% (0) | 12% | $10,369 |
| 2020 | 80 | 50 | 0% (0) | 19% | $4,030 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 15 drugs
| Otezla | 12 | $58,922 | $4,910 |
| Tacrolimus | 15 | $3,326 | $222 |
| Clobetasol Propionate | 35 | $2,657 | $76 |
| Ketoconazole | 59 | $1,308 | $22 |
| Fluorouracil | 16 | $1,249 | $78 |
| Triamcinolone Acetonide | 56 | $979 | $17 |
| Fluocinonide | 18 | $889 | $49 |
| Doxycycline Monohydrate | 12 | $876 | $73 |
| Clindamycin Phosphate | 14 | $825 | $59 |
| Betamethasone Diprop Augmented | 18 | $790 | $44 |
| Ciclopirox | 19 | $630 | $33 |
| Hydrocortisone | 29 | $255 | $9 |
| Mupirocin | 32 | $245 | $8 |
| Doxycycline Hyclate | 11 | $227 | $21 |
| Valacyclovir | 13 | $161 | $12 |
2022: 3 drugs
| Betamethasone Diprop Augmented | 27 | $1,823 | $68 |
| Ketoconazole | 26 | $673 | $26 |
| Triamcinolone Acetonide | 36 | $635 | $18 |
2021: 4 drugs
| Clobetasol Propionate | 14 | $1,683 | $120 |
| Triamcinolone Acetonide | 24 | $328 | $14 |
| Ketoconazole | 16 | $326 | $20 |
| Methotrexate | 13 | $316 | $24 |
2020: 1 drug
| Triamcinolone Acetonide | 11 | $176 | $16 |
Money from drug and device companies
$901 in 2025
| 2025 | 6 | 10 | None | $901 |
| 2024 | 2 | 3 | None | $275 |
| 2023 | 6 | 6 | None | $694 |
| 2022 | 1 | 1 | None | $125 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Galderma Laboratories L.P. | Nemluvio | $386 | 3 payments
|
| Regeneron Pharmaceuticals | Libtayo | $149 | 1 payment
|
| E.R. Squibb & Sons L.L.C. | Sotyktu | $124 | 3 payments
|
| Abbvie | Skyrizi | $115 | 1 payment
|
| Medtronic | Inceptiv | $105 | 1 payment
|
| Abbott Laboratories | Eterna | $22 | 1 payment
|
See all 10 published payments
| Galderma Laboratories L.P. | Meals · 2025-12-16 | Nemluvio | $144 |
| Abbott Laboratories | Meals · 2025-12-09 | Eterna | $22 |
| Regeneron Pharmaceuticals | Meals · 2025-11-19 | Libtayo | $149 |
| Medtronic | Meals · 2025-10-02 | Inceptiv | $105 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-07-31 | Sotyktu | $23 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-07-29 | Sotyktu | $52 |
| Galderma Laboratories L.P. | Meals · 2025-04-30 | Nemluvio | $106 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-04-10 | Sotyktu | $49 |
| Galderma Laboratories L.P. | Meals · 2025-02-18 | Nemluvio | $136 |
| Abbvie | Meals · 2025-01-08 | Skyrizi | $115 |
See earlier years (2024, 2023, 2022)
2024: $275
| Abbott Laboratories | Eterna | $145 | 1 payment
|
| Regeneron Pharmaceuticals | Libtayo | $130 | 2 payments
|
2023: $694
| Dermavant Sciences | Vtama | $148 | 1 payment
|
| Galderma Laboratories L.P. | None | $134 | 1 payment
|
| AbbVie | Rinvoq | $124 | 1 payment
|
| Regeneron Pharmaceuticals | Libtayo | $109 | 1 payment
|
| Janssen Biotech | Tremfya | $95 | 1 payment
|
| Boehringer Ingelheim Pharmaceuticals | None | $83 | 1 payment
|
2022: $125
| Boehringer Ingelheim Pharmaceuticals | None | $125 | 1 payment
|
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| Regeneron Pharmaceuticals, Inc. · A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (Cscc) · 2025 | This clinician | $2,191 |
Professional record
- NPI
- 1518427913
- Licence
- CA A186246California A186246: Current · expires 2027-05-31
- Trained
- Stanford University School of Medicine, 2019
- Video visits
- Lists video visits
- Gender
- Male
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207N00000X (207N00000X); Student in a training program (390200000X)
- Mailing address
- File 57326, Los Angeles, CA, 90074
- NPI first listed
- 2019-03-21
- NPI last updated
- 2024-04-11
- NPI record certified
- 2024-04-11
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 55 Fruit St, Boston, MA, 02114 · 3855 Health Sciences Dr, La Jolla, CA, 92093 · 8899 University Center Ln, San Diego, CA, 92122 · 751 S Bascom Ave, San Jose, CA, 95128